In 2023, Enzo Clinical Labs, a diagnostics and biotech research firm, was hit by a ransomware attack that halted lab operations and compromised sensitive health data. Beyond the immediate disruption, Enzo faced months of investigation and costly recovery efforts because critical data wasn’t restored quickly enough to maintain regulatory continuity.
For biotech companies, that kind of downtime isn’t just an inconvenience. It can stall clinical trials, delay research milestones, and damage relationships with regulators, partners, and investors.
A reliable backup plan is more than a technical safeguard; it’s an executive responsibility. It protects intellectual property, ensures FDA and HIPAA compliance, and preserves business credibility when every hour counts. Below are the five core elements every biotech firm’s leadership team should insist on.
- Define Recovery Objectives That Match Business Reality
A backup plan isn’t effective if it doesn’t align with how your biotech operation functions day to day. C-suites should clearly define Recovery Point Objectives (RPO) and Recovery Time Objectives (RTO) for each critical dataset from genomic libraries to trial documentation.
Key actions to prioritize:
- Map data criticality across all departments (R&D, QA/QC, regulatory, and clinical).
- Define how much data loss (RPO) is acceptable for each system.
- Set realistic recovery windows (RTO) based on operational impact.
- Review and test these thresholds quarterly with both IT and compliance officers.
A practical RPO/RTO strategy transforms backup from a checkbox exercise into a core part of business continuity and regulatory readiness.
- Adopt Immutable and Air-Gapped Backup Storage
When ransomware strikes, traditional backups often get encrypted alongside live systems. That’s why immutable and air-gapped storage has become a best practice in biotech data protection. Immutable backups prevent alteration or deletion, while air-gapped copies remain isolated from the network, safe even from insider or zero-day threats.
C-suite considerations:
- Use storage systems with write-once, read-many (WORM) capabilities to prevent tampering.
- Maintain one or more physically or logically isolated backup copies.
- Integrate ransomware detection and verification before restoring data.
- Ensure that immutability policies align with FDA 21 CFR Part 11 requirements for data integrity and traceability.
Immutable storage is no longer optional, it’s the foundation of data resilience in a sector that lives and dies by the accuracy of its research and records.
- Validate and Test Restorations Regularly
Backup validation is where most organizations fall short. Storing data isn’t enough; you need to prove it can be recovered within compliance parameters. Regulators expect documentation of periodic validation under GxP and Part 11 guidelines.
Implementation best practices:
- Schedule quarterly restoration drills for all mission-critical systems.
- Document each test’s timing, success rate, and data integrity verification.
- Include validation within your internal audit and quality management processes.
- Involve department heads to confirm that restored data is both functional and complete.
These exercises don’t just satisfy auditors they reveal weaknesses in process, vendor coordination, and communication. Testing is the only way to guarantee readiness under real-world pressure.
- Maintain Geographic and Cloud Redundancy
Redundancy ensures your biotech data is available even if an entire site or region becomes inaccessible. Fires, natural disasters, or infrastructure outages can be just as disruptive as cyberattacks. The C-suite should expect redundancy across both physical and cloud environments, with clear documentation on data location and jurisdiction.
Best-practice guidelines:
- Store at least one backup copy in a geographically separate region.
- Use multi-cloud or hybrid approaches to diversify storage risk.
- Confirm that data residency meets HIPAA and FDA global data storage guidelines.
- Evaluate whether your providers support rapid data portability in case of vendor lock-in or geopolitical events.
Geographic redundancy isn’t about duplicating cost, it’s about duplicating assurance. In biotech, where sample data and patient results carry irreplaceable value, one backup location is never enough.
- Integrate Backup Into a Broader Incident Response Plan
A backup plan works best when it’s part of an integrated incident response (IR) framework. Recovery processes shouldn’t exist in isolation, they need executive oversight, communication plans, and defined escalation paths.
Strategic alignment steps:
- Embed backup recovery procedures into your company’s IR and business continuity playbooks.
- Assign clear roles for who initiates recovery, validates data, and communicates externally.
- Conduct annual tabletop exercises that simulate both cyber and operational disruptions.
- Align legal, compliance, and public relations teams with IT to ensure unified responses.
Leadership should treat recovery as a cross-functional exercise, not a technical afterthought. In the eyes of regulators and investors, how you respond is as important as how you prepare.
Building Resilience Beyond Backups
Even with strong backup systems in place, recovery success depends on visibility, testing discipline, and alignment with compliance frameworks. Many biotech firms fail not because their backups were absent, but because they weren’t validated, current, or coordinated across departments.
As seen in the Enzo Clinical Labs case and similar incidents across the healthcare and biotech sectors, delayed restoration can lead to lost data integrity, interrupted testing pipelines, and non-compliance penalties. These are preventable outcomes if leadership treats data recovery as a continuous discipline, not an IT project.
A modern backup strategy should be evaluated at least twice a year, especially as your biotech environment evolves with new lab instruments, hybrid cloud integrations, and expanded remote teams. Every technology shift changes where data lives—and where it must be protected.
Conclusion
A sound backup plan protects more than data, it safeguards years of research, intellectual property, and investor confidence. For biotech firms, resilience is now synonymous with compliance and operational maturity.
At Single Point of Contact, we help biotech organizations strengthen their data continuity strategies through 24/7 monitoring, secure storage architecture, and compliance-aligned recovery frameworks designed around FDA and HIPAA standards. Our role isn’t just to back up your data, it’s to ensure your science and operations never stop moving forward.
About Single Point of Contact
Single Point of Contact is an experienced MSP in the biotech industry and is a valuable partner, providing specialized knowledge in implementing robust backup strategies and ensuring network security and stability. With deep understanding of regulatory requirements such as HIPAA and FDA’s 21 CFR Part 11, Single Point of Contact safeguards sensitive research data, clinical trial information, and intellectual property. They offer tailored solutions, including automated backups, real-time monitoring, and disaster recovery plans, minimizing downtime and data loss. By managing security protocols, they protect against cyber threats, allowing biotech companies to focus on innovation while ensuring compliance and uninterrupted operations. This expertise enhances productivity and reduces risk. Contact us today to discover more about how we can help your biotech firm with DR, backup and security.
